title: The management of alcoholic hepatitis: a prospective comparison of scoring systems.
abstract: BACKGROUND
  The assessment of alcoholic hepatitis remains controversial. Several scores have been developed or used for this purpose.
  
  
  OBJECTIVE
  To study the use of the Glasgow Alcoholic Hepatitis Score (GAHS), the Discriminant Function (DF), Model for End-Stage Liver Disease (MELD) and the ABIC (age, bilirubin, INR and creatinine) scores as well as scores to assess corticosteroid response in the management of alcoholic hepatitis.
  
  
  METHODS
  A total of 182 patients were studied prospectively. The GAHS, MELD, ABIC and DF scores were recorded on admission and serially over the first week of hospital management. Treatment with corticosteroids or pentoxifylline was considered if the GAHS was ≥9.
  
  
  RESULTS
  There were no differences in outcome between favourable scores as per recommended cut-off points. Patients with a GAHS<9 had similar outcome whether their MELD, DF or ABIC scores were favourable or unfavourable. Treated patients with a GAHS≥9 had a significantly better 90-day outcome than those who did not: 58% and 30% respectively, P = 0.01; HR 0.33 (0.14, 0.78). Patients treated with corticosteroids who had a fall in bilirubin of 25% after a week of treatment had an improved survival: 82% compared with 44% [P = 0.0005: HR 3.70 (1.77, 7.73)]. The Lille Score or a 25% fall in bilirubin had greater sensitivities than an early change in bilirubin level (95% and 90% compared with 58%) to assess treatment response.
  
  
  CONCLUSIONS
  In this single-centre study, a GAHS ≥9 identified patients who may benefit from treatment of alcoholic hepatitis. Intention-to-treat randomised-controlled trials using a GAHS ≥9 as the threshold for treatment are needed to validate these findings. Response to corticosteroids can be assessed using the Lille Score or by a 25% fall in bilirubin.
authors.affiliation: Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
authors.forename: H
authors.initials: H
authors.lastname: Lafferty
authors.forename: A J
authors.initials: AJ
authors.lastname: Stanley
authors.forename: E H
authors.initials: EH
authors.lastname: Forrest
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001663:Bilirubin / Q000097:blood; D001798:Blood Proteins / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006519:Hepatitis, Alcoholic / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001798:Blood Proteins; D005938:Glucocorticoids; C024875:platelet adhesion inhibitor; D001663:Bilirubin; D010431:Pentoxifylline